ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0569

All-Cause and Cause-Specific Mortality in Spondyloarthritis: A Systematic Review and Meta-Analysis

Haseeb Chaudhary1, Nidrit Bohra2, Khezar Syed2, Anthony Donato2, M.Hassan Murad3 and Paras Karmacharya4, 1Tower Health System, Reading, PA, 2Reading Hospital, Tower Health System, Reading, PA, 3Mayo Clinic, Rochester, MN, 4Division of Rheumatology, Mayo Clinic, Rochester, MN Division of Rheumatology, Vanderbilt University Medical Center, Nashville, TN

Meeting: ACR Convergence 2021

Keywords: Ankylosing spondylitis (AS), Epidemiology, Mortality, Psoriatic arthritis, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Spondyloarthritides (SpA) represent a group of chronic inflammatory diseases associated with a higher risk of cardio-metabolic comorbidities compared to the general population. It is unclear how these comorbidities are associated with mortality in SpA, and studies on mortality in SpA have shown inconsistent results. We performed a systematic review and meta-analysis of all-cause and cause-specific mortality in psoriatic arthritis (PsA) and ankylosing spondylitis (AS).

Methods: A comprehensive database search was performed for studies reporting all-cause or cause-specific mortality in patients with PsA and AS compared with the general population. Pooled relative risks (RRs) were calculated using random-effects model.

Results: We included 19 studies (eleven for PsA, seven for AS, one for both). In PsA studies, there was no increased mortality compared to the general population (RR: 1.12, 95% CI: 0.96-1.30, 10 studies). Cardiovascular, respiratory, and infection specific mortality risks were significantly higher for PsA patients (RR: 1.21, 95% CI: 1.06-1.38; RR: 3.37, 95% CI: 1.30-8.72; and 2.43, 95% CI: 1.01-5.84, respectively). Cancer related mortality in PsA was not higher than the general population (RR: 1.01, 95% CI: 0.91-1.11). In AS, we found a higher risk of death from all causes (RR 1.64, 95% CI: 1.49-1.80, 6 studies) and cardiovascular causes compared to the general population (RR 1.35, 95% CI: 1.01-1.81, 3 studies).

Conclusion: This systematic review and meta-analysis showed a significantly increased risk of overall mortality in AS, but not PsA. Cardiovascular-specific mortality was higher for both PsA and AS, which emphasizes the importance of early screening and management of comorbidities to mitigate mortality risk.

Figure 1. Prisma Flow Diagram

Figure 2.Forrest Plot for All-cause mortality in A)Psoriatic Arthritis B)Ankylosing Spondylitis

Figure 3.Forrest plot for cause-specific mortality in psoriatic arthritis A) cardiovascular B) respiratory C) infections D) malignancy E) Injury and poisoning


Disclosures: H. Chaudhary, None; N. Bohra, None; K. Syed, None; A. Donato, None; M. Murad, None; P. Karmacharya, None.

To cite this abstract in AMA style:

Chaudhary H, Bohra N, Syed K, Donato A, Murad M, Karmacharya P. All-Cause and Cause-Specific Mortality in Spondyloarthritis: A Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/all-cause-and-cause-specific-mortality-in-spondyloarthritis-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/all-cause-and-cause-specific-mortality-in-spondyloarthritis-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology